US Oncology Research Inc

1. Janssen Research & Development, LLC $9,994,147 2,553 payments
2. GlaxoSmithKline, LLC. $3,343,932 484 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $1,388,384 315 payments
4. Acerta Pharma LLC $858,547 14 payments
5. Radius Health, Inc. $766,024 96 payments
6. Epizyme, Inc., $528,912 42 payments
7. Puma Biotechnology, Inc. $476,694 2 payments
8. Pfizer Inc. $341,730 123 payments
9. TESARO, Inc. $253,119 24 payments
10. AstraZeneca UK Limited $202,365 10 payments

1. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $1,900,774 397 payments
2. A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC $1,203,143 486 payments
3. Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia $1,188,835 478 payments
4. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer $1,068,771 204 payments
5. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $1,008,453 33 payments
6. A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O $891,209 91 payments
7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S $845,757 228 payments
8. A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure $821,420 45 payments
9. A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant $768,060 230 payments
10. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $639,280 50 payments

1. Other $1,388,384 315 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.